Table 3.
Details concerning EIB-positive and EIB-negative athletes.
| EIB (+) (n = 28) | EIB (−) (n = 73) | p | |
|---|---|---|---|
| Asthma (n = 24) | 11 (39%) | 13 (18%) | 0.04455 |
| Nonasthma (n = 77) | 17 (61%) | 60 (82%) | |
| Pre-existing symptoms (n = 54) | 21 (75%) | 33 (45%) | 0.00721 |
| Athletes without pre-existing symptoms (n = 47) | 7 (25%) | 40 (55%) | |
| Athletes reporting cough during exercise (n = 22) | 11 (39%) | 11 (15%) | 0.01778 |
| Athletes reporting dyspnea during exercise (n = 35) | 15 (54%) | 20 (27%) | 0.02504 |
| Athletes who take ICS-LABA * (n = 22) | 11 (39%) | 11 (15%) | 0.01778 |
* Inhaled corticosteroids–long-acting beta-agonists.